Biofrontera Inc. to Report Third Quarter 2026 Financial Results on November 13, 2026
Globe Newswire•06/11/2026•18:08 ET
0
Key Highlights
- ➤Biofrontera will report Q3 2026 financial results before market open November 13
- ➤Management will host a results conference call and webcast at 10:00 a.m. Eastern Time
- ➤FDA approved Biofrontera’s products for superficial basal cell carcinoma in September 2026
WOBURN, Mass., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ: BFRI) ("Biofrontera" or the "Company"), a U.S.-based biopharmaceutical company engaging in the development, manufacturing, and commercialization of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy, today announced that it will report financial results for the third quarter ended September 30, 2026 before the market opens on Friday, November 13, 2026.
Management will host a conference call and webcast the same day at 10:00 a.m. Eastern Time to discuss the results and provide a business update.
Get started
Create a free account to read the full story.